Chemistry:Dipropyldopamine
Dipropyldopamine (DPDA), also known as N,N-di-n-propyldopamine, is a synthetic dopamine receptor agonist related to the catecholamine neurotransmitter dopamine which has been used in scientific research.[1][2] It is a dual agonist of both dopamine D1-like and D2-like receptors, with much greater potency at dopamine D2 receptors than dopamine itself.[2][3] Unlike dopamine, the drug lacks β-adrenergic receptor activity and also has weaker vasoconstrictor effects.[1]
DPDA produces hypolocomotion across a wide range of doses in rodents.[4][5] It modestly reduces climbing behavior at low doses and markedly enhances it at much high doses.[6] The drug is thought to be resistant to metabolism by monoamine oxidase (MAO) but to still be susceptible to metabolism by catechol O-methyltransferase (COMT).[7] It was virtually inactive orally in rodents.[8] In contrast to dopamine, which is peripherally selective, DPDA can cross the blood–brain barrier and produce effects in the central nervous system.[8]
DPDA was first described in the scientific literature by 1977.[9] Other N,N-dialkyl derivatives of dopamine besides DPDA have been studied.[4] In addition, esters of DPDA have been developed and studied.[8]
See also
References
- ↑ 1.0 1.1 "N,N-Di-n-propyl dopamine: a qualitatively different dopamine vascular agonist". The Journal of Pharmacology and Experimental Therapeutics 207 (1): 16–22. October 1978. doi:10.1016/S0022-3565(25)31387-X. PMID 702336.
- ↑ 2.0 2.1 "Peripheral dopamine receptors". American Journal of Hypertension 3 (6 Pt 2): 25S–28S. June 1990. doi:10.1093/ajh/3.6.25s. PMID 2143385.
- ↑ "Molecular Drug Design and Dopamine Receptors". The Dopamine Receptors. Totowa, NJ: Humana Press. 1997. pp. 105–133. doi:10.1007/978-1-4757-2635-0_4. ISBN 978-1-4757-2637-4. http://link.springer.com/10.1007/978-1-4757-2635-0_4. Retrieved 9 February 2026.
- ↑ 4.0 4.1 "Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice". European Journal of Pharmacology 73 (2–3): 175–188. July 1981. doi:10.1016/0014-2999(81)90089-3. PMID 6118281.
- ↑ "Reduction in Spontaneous Locomotor Activity by Purported Dopamine Agonists: an Analysis of the Site and Mechanism of Action". Advances in Dopamine Research. Elsevier. 1982. pp. 413–424. doi:10.1016/b978-0-08-027391-4.50046-0. ISBN 978-0-08-027391-4. https://linkinghub.elsevier.com/retrieve/pii/B9780080273914500460. Retrieved 9 February 2026.
- ↑ "Spontaneous climbing behaviour of mice, its measurement and dopaminergic involvement". European Journal of Pharmacology 85 (2): 125–132. November 1982. doi:10.1016/0014-2999(82)90457-5. PMID 7151866.
- ↑ "Neurochemical and behavioural profiles of five dopamine analogues". Naunyn-schmiedeberg's Archives of Pharmacology 316 (4): 304–310. July 1981. doi:10.1007/BF00501362. PMID 7196506.
- ↑ 8.0 8.1 8.2 "Pivaloyl esters of N,N-dialkylated dopamine congeners. Central dopamine-receptor stimulating activity". Journal of Medicinal Chemistry 21 (9): 864–867. September 1978. doi:10.1021/jm00207a005. PMID 722753.
- ↑ "Dipropyldopamine, a qualitatively different dopamine (DA) agonist.". Federation Proceedings 36 (3): 1049. January 1977. https://scholar.google.com/scholar?cluster=12367958232674843975.
 |  |
